Clinical Trial Update: A Trial of Neoadjuvant mFOLFOXIRI Versus CRT in the EMVI Positive LARC [Phase 2]

View source ↗

Summary

Phase 2 trial update comparing neoadjuvant mFOLFOXIRI to chemoradiation in EMVI-positive locally advanced rectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• MFOLFOXIRI

Snippet

Sponsor: First Affiliated Hospital of Zhejiang University | Conditions: Locally Advanced Rectal Cancer | Phase 2 | Status: UNKNOWN